Anagenex is a pre-clinical biotechnology innovator advancing drug discovery through its small molecule directed evolution platform. The company's unique, machine learning-driven technology enables Anagenex to discover first-in-class and best-in-class small molecule medicines addressing historically intractable targets. With a team of highly experienced scientists and engineers, the company has offices in the San Francisco Bay area and Woburn, Mass.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/08/22 | $30,000,000 | Series A |
Air Street Capital Catalio Capital  Luxor Capital Menlo Ventures Obvious Ventures | undisclosed |
